148 related articles for article (PubMed ID: 22622012)
1. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
[TBL] [Abstract][Full Text] [Related]
2. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel acyl coenzyme a: cholesterol acyltransferase inhibitors: pharmacophore-based virtual screening, synthesis and pharmacology.
Chhabria MT; Brahmkshatriya PS; Mahajan BM; Darji UB; Shah GB
Chem Biol Drug Des; 2012 Jul; 80(1):106-13. PubMed ID: 22429570
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
Lu A; Zhang J; Yin X; Luo X; Jiang H
Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.
Equbal T; Silakari O; Rambabu G; Ravikumar M
Bioorg Med Chem Lett; 2007 Mar; 17(6):1594-600. PubMed ID: 17236767
[TBL] [Abstract][Full Text] [Related]
12. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore identification of Raf-1 kinase inhibitors.
Zhu T; Jiao Y; Chen YD; Wang X; Li HF; Zhang LY; Lu T
Bioorg Med Chem Lett; 2008 Apr; 18(7):2346-50. PubMed ID: 18346893
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.
Bharatham N; Bharatham K; Lee KW
J Mol Graph Model; 2007 Mar; 25(6):813-23. PubMed ID: 16996282
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
Al-Sha'er MA; Taha MO
Eur J Med Chem; 2010 Sep; 45(9):4316-30. PubMed ID: 20638755
[TBL] [Abstract][Full Text] [Related]
17. A three-dimensional pharmacophore model for IMPDH inhibitors.
Yang N; Wang J; Li J; Wang QH; Wang Y; Cheng MS
Chem Biol Drug Des; 2011 Jul; 78(1):175-82. PubMed ID: 21507206
[TBL] [Abstract][Full Text] [Related]
18. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
19. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
20. Ligand and structure-based approaches for the identification of SIRT1 activators.
Vyas VK; Goel A; Ghate M; Patel P
Chem Biol Interact; 2015 Feb; 228():9-17. PubMed ID: 25595223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]